Current status and perspectives of multimodality therapy for hepatocellular carcinoma

Tan YunHua; Shang YangYang; Zhang Tao; Li JianBo; Zheng MingYou

doi:10.3969/j.issn.1001-5256.2019.08.047

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1858-1860

PDF( 1916 KB)

Current status and perspectives of multimodality therapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.08.047

Department of Hepatobiliary Surgery, Chongqing People's Hospital, University of Chinese Academy of Sciences

Research funding:

Received Date: 2019-01-21
Published Date: 2019-08-20

Abstract

Abstract

Hepatocellular carcinoma (HCC) has high morbidity and mortality rates worldwide, and due to the complexity of the development of HCC, the management strategy for HCC has not been completely unified. During the past decade, the treatment of HCC has developed into a multidisciplinary and multimodality therapy centered on surgical operation. Besides hepatectomy and liver transplantation, ablation therapy is another radical treatment, and at present, it can be used as the first-line treatment regimen for HCC patients who have a tumor diameter of < 3 cm and cannot undergo liver transplantation. Transarterial chemoembolization is the preferred treatment for advanced HCC not suitable for radical treatment. Molecular targeted therapy is mainly used in patients who are diagnosed with advanced HCC or progress to advanced HCC after treatment failures. Cellular immunotherapy is a new treatment for HCC and can help patients with progressive HCC to achieve good remission rate and survival benefit. A deep understanding of the features of each treatment method for HCC, development of individualized treatment regimens, and rational multimodality therapy for HCC can help to improve the overall therapeutic outcome of HCC.
- carcinoma, hepatocellular,
- therapeutics,
- prognosis

FullText(HTML)

References(26)

References

[1] CHEN W, SUN K, ZHENG R, et al. Cancer incidence and mortality in China, 2014[J]. Chin Cancer Res, 2018, 30 (1) :1.

[2] TAN Y, JIANG J, WANG Q, et al. Radiofrequency ablation using a multiple-electrode switching system for hepatocellular carcinoma within the Milan criteria:Long-term results[J]. Int J Hyperthermia, 2018, 34 (3) :298-305.

[3] McGUIRE S. World Cancer Report 2014. Geneva, Switzerland:World Health Organization, International Agency for Research on Cancer, WHO Press, 2015[J]. Adv Nutr, 2016, 7 (2) :418-419.

[4] BRUIX J, LLOVET JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma[J]. Hepatology, 2002, 35 (3) :519-524.

[5] YAMASHITA YI, TAKETOMI A, ITOH S, et al. Long term favorable results of limited hepatic resections for patients with hepatocellular carcinoma:20 years of experience[J]. J Am Coll Surgeons, 2007, 205 (1) :19-26.

[6] LLOVET JM, SCHWARTZ M, MAZZAFERRO V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis, 2005, 25 (2) :181-200.

[7] MADDALA YK, STADHEIM L, ANDREWS JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation:Outcome with chemoembolization[J]. Liver Transpl, 2004, 10 (3) :449-455.

[8] YAO FY, BASS NM, ASCHER NL, et al. Liver transplantation for hepatocellular carcinoma:Lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy[J]. Liver Transpl, 2004, 10 (5) :621-630.

[9] TSOULFAS G, KAWAI T, ELIAS N, et al. Long-term experience with liver transplantation for hepatocellular carcinoma[J]. J Gastroenterol, 2011, 46 (2) :249-256.

[10] RAHMAN A, ASSIFI MM, PEDROSO FE, et al. Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis[J]. J Gastrointest Sur, 2012, 16 (10) :1897-1909.

[11] MINAMI Y, KUDO M. Radiofrequency ablation of hepatocellular carcinoma:Current status[J]. World J Radiol, 2010, 2 (11) :417-424.

[12] LENCIONI R, CROCETTI L. Local-regional treatment of hepatocellular carcinoma[J]. Radiology, 2012, 262 (1) :43-58.

[13] GERMANI G, PLEGUEZUELO M, GURUSAMY K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma:A meta-analysis[J]. J Hepatol, 2010, 52 (3) :380-388.

[14] HASEGAWA K, AOKI T, ISHIZAWA T, et al. Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma[J].Ann Surg Oncol, 2014, 21 (3) :348-355.

[15] CHOI D, LIM HK, RHIM H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment:Long-term results and prognostic factors in a large single-institution series[J]. Eur Radiol, 2007, 17 (3) :684-692.

[16] SI TF, CHEN YJ, MA D, et al. Effect of preoperative transarterial chemoembolization on perioperative safety of patients with resectable hepatocellular carcinoma:A Meta-analysis[J].Chin J Dig Surg, 2017, 16 (5) :496-502. (in Chinese) 斯腾飞, 陈拥军, 马迪, 等.术前经导管动脉内化疗栓塞术对可切除性肝细胞癌围术期安全性影响的Meta分析[J].中华消化外科杂志, 2017, 16 (5) :496-502.

[17] YAMAGIWA K, SHIRAKI K, YAMAKADO K, et al. Survival rates according to the Cancer of the Liver Italian Program scores of 345 hepatocellular carcinoma patients after multimodality treatments during a 10-year period in a retrospective study[J]. J Gastroen Hepatol, 2008, 23 (3) :482-490.

[18] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg, 2018, 17 (5) :445-451. (in Chinese) 崔云龙.肝癌的靶向治疗[J].中华消化外科杂志, 2018, 17 (5) :445-451.

[19] ZHANG CY, ZHAO XX, LU ZM, et al. Research advances in sorafenib-induced apoptotic signaling pathways in liver cancer cells[J]. J Clin Hepatol, 2016, 32 (4) :816-820. (in Chinese) 张朝亚, 赵相轩, 卢再鸣, 等.索拉非尼诱导肝癌细胞凋亡信号通路的研究进展[J].临床肝胆病杂志, 2016, 32 (4) :816-820.

[20] LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359 (4) :378-390.

[21] FENG X, XU R, DU X, et al. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1hepatocellular carcinoma:A multicenter retrospective cohort study[J]. Am J Gastroenterol, 2014, 109 (12) :1891-1899.

[22] KUDO M, UESHIMA K, TORIMURA T, et al. Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma:TACTICS trial[J]. J Clin Oncol, 2018, 36 (15 Suppl) :4017.

[23] BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389 (10064) :56-66.

[24] REN ZG. Immunotherapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (7) :1371-1373. (in Chinese) 任正刚.肝细胞癌的免疫治疗[J].临床肝胆病杂志, 2018, 34 (7) :1371-1373.

[25] SANMAMED MF, CHEN L. A paradigm shift in cancer immunotherapy:From enhancement to normalization[J]. Cell, 2019, 176 (3) :677.

[26] EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate040) :An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389 (10088) :2492-2502.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(14)

1.	周凤玲，陈婉君，黄德伦，马远征，袁彬，叶一娴，韦晓洁，韦燕飞. 白花丹醌抑制肝癌类干细胞增殖迁移及干性转录因子的表达. 海南医学院学报. 2024(14): 1059-1067 .
2.	王楠，薛国亮，徐静雯，危志刚，叶欣. 微波消融在载药微球经肝动脉化疗栓塞术联合靶向和免疫治疗进展期原发性肝癌中的应用. 中华肿瘤防治杂志. 2023(14): 865-870 .
3.	刘莹，高本见，杨小李，方程，苏松，李波. 半肝阻断法和全肝阻断法在原发性肝癌肝切除术中应用效果比较的Meta分析. 临床肝胆病杂志. 2021(01): 73-78 . 本站查看
4.	李光骁，肖鹏，甄育兰，周丽玲. 调强放疗联合经皮肝动脉化疗栓塞在肝细胞癌合并门静脉癌栓中的治疗进展. 现代医学与健康研究电子杂志. 2021(11): 140-142 .
5.	王嫚，刘爱连，赵莹，林涛，王楠，宋清伟，郭妍，李昕，吴艇帆. 基于扩散张量成像的纹理分析鉴别肝细胞癌和肝内胆管细胞癌的价值. 磁共振成像. 2021(08): 15-21 .
6.	叶定德，王剑，彭进，孙倍成，徐庆祥. 肝细胞癌转化治疗方法及其适应证的选择. 中华医学杂志. 2021(28): 2259-2262 .
7.	古丽巴哈尔·卡吾力，马建宝，艾克山·吾拉木，衣再提古丽·外力，阿力米江·奥布力塔力甫. 黑果枸杞总黄酮对HepG-2细胞增殖与凋亡的影响. 食品安全质量检测学报. 2021(17): 7014-7020 .
8.	罗容，李娜，乔飞，石睿，任荣荣，李勇. 能谱CT定量参数对肝细胞癌微血管侵犯的评估价值. 中国CT和MRI杂志. 2021(11): 105-108 .
9.	张宇. 肝动脉化疗栓塞联合射频消融治疗肝癌疗效及预后分析. 航空航天医学杂志. 2021(11): 1313-1314 .
10.	徐莹，任雪，佟昌慈，武忠宝，柳云恩，阎英. 猕猴桃根提取物抗肝细胞癌作用及相关机制研究. 临床军医杂志. 2020(02): 128-132 .
11.	王秀丽，黄清勇，吴玉英. 甲胎蛋白异质体比率和血清异常凝血酶原联合检测对肝细胞癌的临床诊断价值. 中外医学研究. 2020(06): 75-77 .
12.	张媛，陈晓蓉，杨宗国. 多聚免疫球蛋白受体在肝细胞癌发病及诊治中的作用. 临床肝胆病杂志. 2020(07): 1643-1645 . 本站查看
13.	江杰，胡宗强，陈刚，徐源通，褚光. 原发性肝癌转化治疗研究进展. 临床肝胆病杂志. 2020(08): 1870-1873 . 本站查看
14.	吴晓庆，万红，杨璞叶，钱宏波，靳稳妮，兰琳. miR-1266靶向DAB2IP调控肝癌细胞的增殖和凋亡. 胃肠病学和肝病学杂志. 2020(10): 1179-1184 .

Other cited types(13)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1266) PDF downloads(383)

Current status and perspectives of multimodality therapy for hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2019.08.047